BIO vs CDTX · rev $2.58B vs rev $1.3M
BIO (BIO) versus Cidara Therapeutics Inc (CDTX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
BIO currently screens at market cap $0. CDTX currently screens at market cap $6.96B.
Not investment advice. Open the BIO and CDTX stock pages for the full models.
Not investment advice.